Physician profile
Julia Rittenhouse
NPI 1013329622
$1,257.91
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $870 · 2020: $320 · 2021: $67.66.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $218.02 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $196.44 | 2019-2020 | |
| Pfizer INC. | $148.97 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $130.12 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $126.61 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.75 | 2019-2020 | |
| Abbvie INC. | $67.66 | 2021 | |
| Sanofi-Aventis U.S. LLC | $55.92 | 2019-2020 | |
| Lilly USA, LLC | $53.69 | 2019-2020 | |
| Novo Nordisk INC | $53.09 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $43.40 | 2019-2020 | |
| Allergan, INC. | $26.24 | 2019-2020 | |
| Sanofi Pasteur INC. | $13.65 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.03 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.32 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Rittenhouse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.